Dyadic International, Inc., a global biotechnology company, discovers, develops, manufactures, and sells enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical, and industrial enzyme industries. The company utilizes an integrated technology platform based on its patented and proprietary C1 fungus (the C1 Platform Technology), which enables the development and manufacture of enzymes and other proteins for diverse market opportunities. In addition to facilitating the development and production of enzymes and other proteins, the C1 Platform Technology has the potential of developing and producing other biological products, such as antibodies, vaccines, proteins and polypeptides for the biopharmaceutical industry. The company manufactures enzymes using its proprietary and patented C1 and Trichoderma industrial strains and sells those enzymes in various industrial markets, including animal feed, food and beverage, pulp and paper, and textiles. The company licenses its patented and proprietary technologies; sells its proprietary enzymes; and conducts research and development activities for third parties. Its research and development activities focus on its patented and proprietary fungal strains and associated technologies. In particular, it uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. The company manufactures and sells liquid and dry enzyme products to global customers for use within the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and biofuels industries. The company also utilizes an integrated technology platform based on its patented and proprietary C1 fungus (the C1 Platform Technology), which enables the development and large-scale manufacture of enzymes and other proteins for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. The company utilizes, among other proprietary technologies, the C1 Expression System, an integrated technology platform based on its patented and proprietary C1 microorganism. The C1 Expression System enables the development and large scale manufacture of enzymes and other proteins for various opportunities. The technology can also be used to screen for the discovery of novel genes. Intellectual Property The company’s patent portfolio includes 15 U.S. patents and 41 foreign patents for claims that cover the Dyadic C1 technology platform, and a total of 32 U.S. and foreign filed and pending patent applications. The company’s primary family of patents protects the commercial development and use of various C1 organisms, the C1 Expression System, certain C1 molecular tools, such as promoters, as well as specific C1 genes and C1 enzymes among other IP. These patents consist of an intellectual property portfolio that protects its C1 Expression System and the products derived from it. The company also has a family of patents that among other applications protect its use of enzymes and enzyme combinations in the biofuels and bio-based chemicals end-markets. Customers The company’s customers for its industrial enzymes are primarily distributors, enzyme formulators, and other value-added resellers. Its main technology licensees include, BASF SE; Codexis, Inc.; and the animal nutrition company. The company provides its C1 technology to Abengoa Bioenergy and Compagnie Industrielle de la Matière Vegetale. Sales and Marketing The company’s business-to-business model of selling primarily to distributors and formulators allows it to maintain a relatively small sales team. It has salespeople working remotely in Hong Kong, The Netherlands, Germany, Brazil, North Carolina, and Minnesota. Collaborations The company has research and development collaborations with Wageningen University; The Scripps Research Institute (Scripps Florida); Moscow State University; The Netherlands Organization; and Bio-Technical Resources. The company has public-private research partnerships with OPTIBIOCAT; Bakenzyme; Healthbread; Bio-Mimetic; Chit4Value; DISCOX; and Parenco. Regulatory Environment The company develops products derived from both genetically modified organisms (GMO) and non-GMOs that are subject to regulation by federal, state, local, and foreign governmental agencies. Some of its existing products required the U.S. Food and Drug Administration approval. In the U.S., the company’s biofuels business is the beneficiary of the Federal Renewable Fuel Standard, a program established and administered by the Environmental Protection Agency. History Dyadic International, Inc. was founded in 1979 by Mark A. Emalfarb.
dyadic international inc (DYAI:OTC US)
140 Intracoastal Pointe Drive
Jupiter, FL 33477
|Koninklijke DSM NV||€50.46 EUR||+1.19|
|Lonza Group AG||SFr.123.90 CHF||+6.30|
|Merck KGaA||€97.78 EUR||+1.36|
|Novozymes A/S||kr317.00 DKK||-0.30|
|Teva Pharmaceutical Industries Ltd||$56.51 USD||-0.05|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact DYADIC INTERNATIONAL INC, please visit www.dyadic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.